摘要
目的探讨基质金属蛋白酶-9(MMP-9)及其抑制剂1(TIMP-1)在糖皮质激素(简称激素)治疗重度慢性阻塞性肺疾病急性加重期(AECOPD)的变化及意义。方法以双抗体夹心EUSA法检测AECO—PD患者激素治疗组(41例)和对照组(40例)治疗前后血清MMP-9和TIMP-1水平,并分析与肺功能的关系。结果①AECOPD激素治疗组血清MMP-9、TIMP-1浓度、MMP-9/TIMP-1比值[分别为(189.25±52.38)μg/L,(198.38±43.45)μg/L,0.92±0.37]明显低于治疗前[(246.10±68.64)μg/L,(217.63±62.34)μg/L,1.09±0.23],差异均有统计学意义(P〈0.01,P〈0.05,P〈0.05);对照组治疗后MMP-9、TIMP-1、MMP-9/TIMP-1下降,但治疗前、后比较差异无统计学意义(P均〉0.05)。②激素治疗组治疗后1秒钟用力呼气容积(FEV1l)、FEV1占正常预计值百分比[(0.83±0.35)L,(46±17)%]比治疗前[(0.72±0.48)L,(34±15)%]有明显改善(P均〈0.05)。结论糖皮质激素治疗后患者MMP-9、TIMP-1、MMP-9/TIMP-1下降,FEV1%占正常预计值有明显改善;协调MMP-9/TIMP-1比例失衡,可能是糖皮质激素治疗重度AECOPD机制之一。
Objective To explore the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with acute exacerbation of severe chronic obstructive pulmonary diseases (AECOPD) treated with glucocorticoids. Methods The serum /evels of MMP-9 and TIMP-1 were measured by ELISA in 41 patients with AECOPD before and after treatment with glucocorticoids and in 40 patients with regular methods( control group). Results ①After treatment with glucocorticoids, the serum levels of MMP-9 ( 189.25 ± 52.38 ) μg/L,TIMP-1 ( 198.38±43.45 ) μg/L, ratio of MMP-9/TIMP-1 (0.92±0.37 ) were decreased significantly than before ( ( 246.10±68.64 ) μg/L, ( 217.63±62.34 ) μg/L, ( 1.09 ± 0.23 ) ) ( P 〈 0.01, P 〈 0.05, P 〈 0.05 ) ; but there were no differences (P 〉 0.05 ) in regular methods (control group) ;②After treatment with glucocorticoids, FEV1, FEV1% ( (0.83 ± 0.35 ) L, ( 46 ± 17 ) % ) were improved than before ( ( 0.72 ±0.48 ) L, ( 34 ± 15 ) % ) ( P 〈 0.05). Conclusions After treatment with glucocorticoids, the serum levels of MMP-9, TIMP-1, ratio of MMP-9/ TIMP-1 from patients with COPD were decreased significantly, and FEV1 ,FEV1% were improved significant; Glueocortieoids can alleviate severe AECOPD to some degrees, which might be related to improving the imbalance of MMP-9/TIMP-1.
出处
《中国综合临床》
2010年第1期38-40,共3页
Clinical Medicine of China